This article is more than 5 years old. Information may no longer be current.
Vascular normalization after single-dose cediranib predicted survival for recurrent glioblastoma
Click Here to Manage Email Alerts
AACR 100th Annual Meeting
A biomarker has been identified that may help to identify patients with recurrent glioblastoma who stand to respond better to anti-VEGF endothelial growth factor therapy with cediranib.
In a phase-2 study, Rakesh K. Jain, PhD, Andrew Werk Cook Professor of Tumor Biology at Harvard Medical School, and colleagues found that patients whose blood vessels had “normalized” the most after treatment had delayed progression and better survival.
They measured vascular normalization one day after patients received cediranib using an advanced MRI technique. They also performed blood analysis and examined correlations between vascular parameters and treatment response after a single dose in 31 patients with recurrent glioblastoma.
The vascular normalization index was made up of three parameters: changes in MRI-measured vascular permeability/flow and microvessel volume, and circulating collagen IV compared to baseline. Changes in these three parameters separately correlated with duration of OS and PFS (P<.05). Combined into a “vascular normalization index,” they were more closely associated with both OS (P=.004) and PFS (P=.001).
“When patients were divided into four quartiles, those with the 25% highest normalization index live longer, with median survival of about a year,” Jain said. “This was in contrast to patients whose blood vessels did not normalize, who had a median survival of less than six months.”
For more information:
More AACR meeting highlights >>